Schwarz Pharma Announces -- Rotigotine CDS Patch: A Novel Transdermal Continuous Delivery System – The Future in Parkinson’s Disease Therapy
Comments by Professor Rascol of INSERM France, Professor Chase of NIH and Professor LeWitt of the Neuroscience Center in Michigan reflect that a continuous delivery system of dopamine agonist to the brain would benefit Parkinson’s disease patients
Hopkinton, MA - Nov 25, 2002 - Aderis Pharmaceutical’s partner for rotigotine CDS, Schwarz Pharma, released the findings of several researchers as presented at the 7th International Congress of Parkinson’s Disease and Movement Disorders held in Miami Florida earlier this month. Read the complete news release from Schwarz Pharma.
"At Aderis, we are excited about the progress of our product candidates and their potential ability to improve quality of life for millions of people. We are committed to helping patients and investors understand our progress as we achieve corporate and clinical milestones."
-Kenneth L. Rice, Jr.,
Chief Commercial Officer, Aderis Pharmaceuticals
back to top
